Response to Eribulin in a Difficult-To-Treat Triple Negative Breast Cancer Patient-Juniper Publishers



In this paper, we report our experience with eribulinmesylate in a locally advanced triple negative breast cancer (BC) patient who was treated with antracyclines and taxanes, and became metastatic. After one refractory line with Capecitabine and Bevacizumab, there was response to Eribulin. No unexpected acute toxicity was observed.

https://juniperpublishers.com/ijcsmb/IJCSMB.MS.ID.555559.php


For more Open access journals please click on JuniperPublishershttps://juniperpublishers.com/



Comments

Popular posts from this blog

Autoimmune Diseases and Inflammatory Disorders of Unknown Etiology; Contemplating Causation and Implication in Public Health Protection- Juniper Publishers

Therapeutic Potential of Folk Plants Used Against Pathogenic and Opportunistic Free Living Amoeba- Juniper Publishers